Navigation Links
Defective signaling pathway sheds light on cystic fibrosis
Date:2/14/2010

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signaling pathway that contributes to disease severity. In the study, published in the journal Nature Medicine, the researchers report that defective signaling for a protein called the peroxisome proliferator-activated receptor-γ (PPAR-γ) accounts for a portion of disease symptoms in cystic fibrosis, and that correction of the defective pathway reduces symptoms of the disease in mice.

In the paper published in the February 14 edition of the journal, lead investigator Gregory Harmon, MD, study supervisor Christopher Glass, MD, PhD, professor of cellular and molecular medicine, and colleagues show that both mice and cells from patients with cystic fibrosis have a defect in signaling for PPAR-γ, as a result of reduced levels of prostaglandins that activate the receptor.

Cystic fibrosis is the most common, potentially lethal genetic disease among whites, occurring in one in 3,000 births. The disease is a multisystem condition that leads to progressive lung failure, pancreatic failure and gastrointestinal obstruction, or blockage.

"Cystic fibrosis results from a genetic mutation in a channel, or membrane pore, that facilitates the transport of chloride and bicarbonate electrolytes from inside the cell to the spaces outside the cell," said Harmon. "Loss of the cystic fibrosis pore channel results in inflammation and mucus accumulation. It also results in dehydration of the cell surfaces that make up the lining spaces inside the lungs and other affected organs, such as the intestinal tract."

Exactly how the process occurs has been a matter of intense scientific scrutiny; yet despite numerous therapeutic advances, individuals with the disease continue to endure a shortened lifespan. "Someone born in the 1990s with cystic fibrosis is expected to live to an age of around 40," Harmon added.

Working with isolated cells from mice and human cell lines from patients with the disease, Harmon identified that multiple genes affected by PPAR-γ were reduced in cystic fibrosis. When the researchers treated mice with cystic fibrosis with the drug rosiglitazone, a thiazolidinedione drug that binds and activates PPAR-γ, gene expression was largely normalized and survival improved. The drugs also corrected part of the inflammatory process in the tissue. Deleting the PPAR-γ protein in the intestine of mice worsened the disease, leading to mucus accumulation in the intestine. Additionally, the researchers found that activating PPAR-γ could increase bicarbonate production in the intestinal tissue by increasing the activity of bicarbonate-producing enzymes called carbonic anhydrases.

"For the first time, we are able to use a drug that activates bicarbonate transport without affecting chloride transport, and see improvement in the disease," Harmon said. The results provide support for the hypothesis of experts in the field such as UCSD's Paul Quinton, PhD, who has written that increasing bicarbonate in cystic fibrosis tissues could be a relevant target for future therapies.

"The finding of the reduced PPAR-γ activating prostaglandin in cystic fibrosis is exciting since it could serve as a marker to identify which patients might benefit from treatment with PPAR-&gamm activating drugs," said Glass.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Quality control mechanism tags defective sperm cells inside the body
2. Defective Chinese Drywall Lawsuit: Florida Homeowners' Associations and Condominium Associations Plagued by Defective Chinese Drywall Urged to Investigate their Rights
3. Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall
4. Consumer Group Releases New Study About Defective Heart Devices and Implants; Patients Arrive in DC Tomorrow
5. Emory researchers identify signaling protein for multiple myeloma
6. Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney
7. Scientists shed light on long-distance signaling in developing neurons
8. St. Jude finds signaling system that halts the growth of a childhood brain cancer
9. Signaling protein helps limit damage in heart attack, Jefferson scientists show
10. Model offers new understanding of cell signaling
11. Researchers learn how signaling molecule orchestrates breast cancers spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... “The Road To Restoration”: an informative and enlightening book for ... week showing of hands. “The Road To Restoration” is the creation of published author, ... the brass ring that you could reach out for, and grab, on the old ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
(Date:12/6/2016)... ... December 06, 2016 , ... The International Vaccine ... a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will ... Korea for emergency deployment in the event of a future outbreak. , IVI ...
(Date:12/6/2016)... ... December 06, 2016 , ... i2i Population Health, a ... a vice president of sales. , “Ajdin understands that building a successful sales ... understand what each client needs, and is persistent in building towards a solution ...
(Date:12/6/2016)... Scottsdale, Arizona (PRWEB) , ... December 06, 2016 , ... ... less than fIve days after launch. Almost 200 backers pledged more than $25,000 ... life-changing technology. , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... N.Y. , Dec. 6, 2016 ... a reason to be hopeful.  A special kind of ... a less anxious life. Photo - ... Robert Buck, the psychotherapist who developed and ... breakthrough approach to overcoming anxiety and worry.  "Anxiety ...
(Date:12/5/2016)... , Dec. 5, 2016  Zimmer Biomet Holdings, ... announced that, pursuant to its previously-announced cash tender ... in the table below (collectively, the "Notes"), approximately ... validly tendered and not validly withdrawn on or ... time, today, December 5, 2016 (the ...
(Date:12/5/2016)... France Glaucoma Surgery Devices Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... value, in millions of US dollars, volume (in units) ... Micro Catheters and Glaucoma Drainage Devices. The report ... each of these market segements, and global corporate-level profiles ...
Breaking Medicine Technology: